Regulation of T cell function by enzymatic proteolysis of L-selectin (360G-Wellcome-094511_Z_10_A)

£68,092

Our experiments are directed at enhancing the potency of adoptive T cell immunotherapy (ACT). To date, all three applicants have made a series of independent observations on different aspects of T cell biology following genetic manipulation of mouse T cells. Each of these genetic changes has had the effect of significantly promoting anti-tumour immune responses. A natural progression of these findings, to be pursued in this grant, is to explore in the context of adoptive T cell immunotherapy, the potential overlapping, additive or synergistic effects of combining these genetic manipulations of T cells. Specifically, in this proposal we will: Determine whether adoptive transfer of CD8 T cells with maintained L-selectin and/or deficiency in SHP-1 induces regression of vascularised tumours in mouse Determine whether the removal of Tregs from the tumour bearing hosts has an additional or synergistic effect on CD8 mediated tumour regression in mice Determine whether human CD8+ T cell reactivity to tumour antigens can be similarly modified by maintained L-selectin and/or SHP-1 deficiency and whether sensitivity to Tregs is altered

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 68092
Applicant Surname Ager
Approval Committee Science Enhancement Committee
Award Date 2013-10-03T00:00:00+00:00
Financial Year 2013/14
Grant Programme: Title Enhancement
Internal ID 094511/Z/10/A
Lead Applicant Prof Ann Ager
Partnership Value 68092
Planned Dates: End Date 2017-04-30T00:00:00+00:00
Planned Dates: Start Date 2013-11-01T00:00:00+00:00
Recipient Org: Country United Kingdom
Region Wales